The multi-centre, double-blind, randomised, placebo-controlled phase-3 trial was launched in August last year to evaluate the jab’s efficacy, safety and long-term immunogenicity
The multi-centre, double-blind, randomised, placebo-controlled phase-3 trial was launched in August last year to evaluate the jab’s efficacy, safety and long-term immunogenicity